Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the hematological response rate, as well as
other parameters of efficacy and safety induced by tipifarnib in patients with high-risk
myelodysplastic syndrome (MDS). Tipifarnib belongs to a class of drugs called Farnesyl
Transferase Inhibitors (FTI). It blocks proteins that make cancer cells grow.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.